All infiltrating T-lymphocytes in Hodgkin's disease express immunohistochemically detectable T-cell receptor ζ-chains in situ

Histopathology

Volumn 36, Issue 6, 2000, Pages 544-550

  Dukers, D F ^a,c   Oudejans, J J ^a   Jaspars, E H ^a   Gras, M ^a   Vos, W ^a   Middeldorp, J M ^a,b   Meijer, C J L M ^a   Bloemena, E ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b Bioscience Research Unit   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Hodgkin's disease; Immune escape; Immunohistochemistry; TCR chain

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; PARAFFIN; T LYMPHOCYTE RECEPTOR;

ADOLESCENT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; FROZEN SECTION; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; LYMPHOCYTE DIFFERENTIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; STORAGE; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD8; CHILD; FEMALE; FROZEN SECTIONS; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PARAFFIN EMBEDDING; RECEPTORS, ANTIGEN, T-CELL; TIME FACTORS; TISSUE PRESERVATION;

HUMAN HERPESVIRUS 4;

EID: 0034038662     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2000.00909.x     Document Type: Article

References (35)

1. 1. Klein G. The Epstein-Barr Virus. In Epstein MA, Achong BG, eds. Berlin: Springer Verlag, 1979: 339.
2. 2. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N. Engl. J. Med. 1989: 320; 502-506.
3. 3. Zur-Hausen H, Schulte-Holthausen H, Klein G et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinoma of the nasopharynx. Nature 1970: 228; 1056-1058.
4. 4. Wolf H, Zur-Hausen H, Klein G, Becker V, Henle G, Henle W. Attempts to detect virus-specific DNA sequences in human tumors. III. Epstein-Barr viral DNA in non-lymphoid nasopharyngeal carcinoma cells. Med. Microbiol. Immunol. 1975: 161; 15-21.
5. 5. Craig FE, Gulley ML, Banks PM. Posttransplantation lymphoproliferative disorders. Am. J. Clin. Pathol. 1993: 99; 265-276.
6. 6. Hamilton-Dutoit SJ, Pallesen G, Franzmann MB et al. AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am. J. Pathol. 1991: 138; 149-163.
7. 7. Weiss LM, Strickler JG, Warnke RA, Purtilo DT, Sklar J. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am. J. Pathol. 1987: 129; 86-91.
8. 8. Libetta CM, Pringle JH, Angel CA, Craft AW, Malcolm AJ, Lauder I. Demonstration of Epstein-Barr viral DNA in formalin fixed, paraffin embedded samples of Hodgkin's disease. J. Pathol. 1990: 161; 255-260.
9. 9. Thorley-Lawson DA, Israelsohn ES. Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein. Proc. Natl. Acad. Sci. USA 1987: 84; 5384-5388.
10. 10. Khanna R, Burrows SR, Nicholls J, Poulsen LM. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur. J. Imunol. 1998: 28; 451-458.
11. 11. Rickinson AB, Moss DJ, Allen DJ, Wallace LE, Rowe M, Epstein MA. Reactivation of Epstein-Barr virus specific cytotoxic T cells by in vitro stimulation with the autologous lymphoblastoid cell line. Int. J. Cancer 1981: 27; 593-601.
12. 12. Oudejans JJ, Jiwa NM, Kummer JA et al. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus positive and negative Hodgkin's disease. Blood 1996: 87; 3844-5851.
13. 13. Oudejans JJ, Jiwa NM, Kummer JA et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 1997: 89; 1376-1382.
14. 14. Han T, Minowada J. Impairment of cell mediated immunity in untreated Hodgkin's disease. N Y State J. Med. 1978: 2; 216.
15. 15. Rickinson AB, Murray RJ, Brooks JM, Griffin H, Moss DJ, Masucci MG. T cell recognition of Epstein-Barr virus associated lymphomas. Cancer Surv. 1992: 13; 53-80.
16. 16. Maggi E, Parronchi P, Macchia D, Piccinni MP, Simonelli C, Romagmini S. Role of T cells in the pathogenesis of Hodgkin's disease. Int. Rev. Exp. Pathol. 1992: 33; 141-164.
17. 17. Slivnick DJ, Ellis TM, Nawrocki JF, Fisher RI. The impact of Hodgkin's disease on the immune system. Semin. Oncol. 1990: 17; 673-682.
18. 18. Renner C, Ohnesorge S, Held G et al. T cells from patients with Hodgkin's disease have a defective T-cell receptor ζ chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood 1996: 88; 236-241.
19. 19. Faguet GB, Davis HC. Survival in Hodgkin's disease: The role of immunocompetence and other major risk factors. Blood 1982: 59; 938-945.
20. 20. Roskrow MA, Suzuki N, Gan YJ et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998: 91; 2925-2934.
21. 21. Sussman JJ, Bonifacino JS, Lippincott-Schwartz J et al. Failure to synthesize the T cell CD3 ζ chain: structure and function of a partial T cell receptor complex. Cell 1988: 52; 85-95.
22. 22. Mulder WM, Bloemena E, Stukart MJ, Kummer JA, Wagstaff J, Scheper RJ. T-cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut 1997: 40; 113-119.
23. 25. Nagakomi H, Petersson M, Magnussen M et al. Decreased expression of the signal-transducing ζ chains in tumor infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cam IT Res. 1993: 53; 5610-5612.
24. 24. Buggins AGS, Hirst WJR, Pagliuca A, Mufti GJ. Variable expression of CD3-zeta and association protein kinases in lymphocytes from patients with myeloid malignancies. Br. J. Haematol. 1998: 100; 784-792.
25. 25. Finke JH, Zea AH, Stanley J et al. Loss of T-cell receptor ζ chain and p56 1ck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993: 53; 5613-5616.
26. 26. Healy CG, Simons JW, Carducci MA et al. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 1998: 32; 109-119.
27. 27. Trimble LA, Lieberman J. Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3-zeta, the signalling chain of the T-cell receptor complex. Blood 1998: 91; 585-594.
28. 28. Reichert TE, Day R, Wagner EM, Whiteside TL. Absent or low expression of ζ chain in T cells at the tumour site correlates with poor survival in patients with oral carcinoma. Cancer Res. 1998: 58; 5344-5347.
29. 29. Lukes RJ, Craver LF, Hall TC, Rappaport H, Ruben P. Report of the nomenclature committee. Cancer Res. 1966: 26; 1311.
30. 30. Jiwa NM, Kanavaros P, De Bruin PC et al. Presence of Epstein-Barr virus harbouring small and intermediate-sized cells in Hodgkin's disease: is there a relationship with Reed-Sternberg cells? J. Pathol. 1993: 170; 129-136.
31. 31. Oudejans JJ, Kummer JA, Jiwa M et al. Granzyme B expression in Reed-Sternberg cells of Hodgkin's disease. Am. J. Pathol 1996: 148; 233-240.
32. 32. Bobrow MN, Shaughnessy KJ, Litt GJ. Catalysed reporter deposition: a novel method of signal amplification. II Application to membrane immunoassays. J. Immunol. Meth. 1989: 125; 279-288.
33. 33. Raap AK, van der Corput MPC, Vervenne RAW, Gijlswijk van RPM, Tanke HJ, Wiegant J. Ultra sensitive FISH using peroxidase-mediated deposition of biotin or fluorochrome tyramides. Human Mol. Gen. 1995: 4; 529-534.
34. 34. Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J. Natl. Cancer Inst. 1996: 88; 1054-1059.
35. 35. Rubin B, Martin EPG, Arnaud J et al. Expression and signal transduction of T-cell antigen receptor (TCR) /CD3 complexes on fresh or in vitro expanded T lymphocytes from patients with Hodgkin's disease and non-Hodgkin's lymphomas. Scan. J. Immunol. 1997: 45; 715-725.